189 related articles for article (PubMed ID: 34455369)
1. Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells.
Kondo N; Nagano Y; Hasegawa A; Ishizawa M; Katagiri K; Yoneda T; Masuda T; Kannagi M
Biochem Biophys Res Commun; 2021 Oct; 574():104-109. PubMed ID: 34455369
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K; Søgaard Helbo A; Fibiger Munch-Petersen H; Sjö L; Christensen J; Sommer Kristensen L; Asmar F; Hermansen NEU; O'Connel C; Gimsing P; Liang G; Grønbaek K
Mol Oncol; 2018 Feb; 12(2):180-195. PubMed ID: 29130642
[TBL] [Abstract][Full Text] [Related]
3. Long Noncoding RNA ANRIL Supports Proliferation of Adult T-Cell Leukemia Cells through Cooperation with EZH2.
Song Z; Wu W; Chen M; Cheng W; Yu J; Fang J; Xu L; Yasunaga JI; Matsuoka M; Zhao T
J Virol; 2018 Dec; 92(24):. PubMed ID: 30258009
[TBL] [Abstract][Full Text] [Related]
4. Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of Crbn
Röhner L; Ng YLD; Scheffold A; Lindner S; Köpff S; Brandl A; Beilhack A; Krönke J
Exp Hematol; 2021 Jan; 93():61-69.e4. PubMed ID: 33186626
[TBL] [Abstract][Full Text] [Related]
5. CK1α and IRF4 are essential and independent effectors of immunomodulatory drugs in primary effusion lymphoma.
Patil A; Manzano M; Gottwein E
Blood; 2018 Aug; 132(6):577-586. PubMed ID: 29954751
[TBL] [Abstract][Full Text] [Related]
6. ARID2 is a pomalidomide-dependent CRL4
Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma.
Zhu YX; Kortuem KM; Stewart AK
Leuk Lymphoma; 2013 Apr; 54(4):683-7. PubMed ID: 22966948
[TBL] [Abstract][Full Text] [Related]
8. Peridinin, a carotenoid, inhibits proliferation and survival of HTLV-1-infected T-cell lines.
Ishikawa C; Jomori T; Tanaka J; Senba M; Mori N
Int J Oncol; 2016 Oct; 49(4):1713-21. PubMed ID: 27499015
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulatory drugs target IKZF1-IRF4-MYC axis in primary effusion lymphoma in a cereblon-dependent manner and display synergistic cytotoxicity with BRD4 inhibitors.
Gopalakrishnan R; Matta H; Tolani B; Triche T; Chaudhary PM
Oncogene; 2016 Apr; 35(14):1797-810. PubMed ID: 26119939
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 4 as a therapeutic target in adult T-cell leukemia lymphoma.
Rauch DA; Olson SL; Harding JC; Sundaramoorthi H; Kim Y; Zhou T; MacLeod AR; Challen G; Ratner L
Retrovirology; 2020 Aug; 17(1):27. PubMed ID: 32859220
[TBL] [Abstract][Full Text] [Related]
11. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity.
Gandhi AK; Mendy D; Waldman M; Chen G; Rychak E; Miller K; Gaidarova S; Ren Y; Wang M; Breider M; Carmel G; Mahmoudi A; Jackson P; Abbasian M; Cathers BE; Schafer PH; Daniel TO; Lopez-Girona A; Thakurta A; Chopra R
Br J Haematol; 2014 Jan; 164(2):233-44. PubMed ID: 24206017
[TBL] [Abstract][Full Text] [Related]
12. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.
Zhu YX; Braggio E; Shi CX; Bruins LA; Schmidt JE; Van Wier S; Chang XB; Bjorklund CC; Fonseca R; Bergsagel PL; Orlowski RZ; Stewart AK
Blood; 2011 Nov; 118(18):4771-9. PubMed ID: 21860026
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cross-priming of naive CD8+ T cells by dendritic cells treated by the IMiDs® immunomodulatory compounds lenalidomide and pomalidomide.
Henry JY; Labarthe MC; Meyer B; Dasgupta P; Dalgleish AG; Galustian C
Immunology; 2013 Jul; 139(3):377-85. PubMed ID: 23374145
[TBL] [Abstract][Full Text] [Related]
14. Expression of the cereblon binding protein argonaute 2 plays an important role for multiple myeloma cell growth and survival.
Xu Q; Hou YX; Langlais P; Erickson P; Zhu J; Shi CX; Luo M; Zhu Y; Xu Y; Mandarino LJ; Stewart K; Chang XB
BMC Cancer; 2016 May; 16():297. PubMed ID: 27142104
[TBL] [Abstract][Full Text] [Related]
15. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells.
Galustian C; Meyer B; Labarthe MC; Dredge K; Klaschka D; Henry J; Todryk S; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB; Dalgleish AG
Cancer Immunol Immunother; 2009 Jul; 58(7):1033-45. PubMed ID: 19009291
[TBL] [Abstract][Full Text] [Related]
16. IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells
Wang Y; Shimosaki S; Ikebe E; Iha H; Yamamoto JI; Fife N; Ichikawa T; Hori M; Ogata M; Tsukamoto Y; Hijiya N; Moriyama M; Hagiwara S; Kusano S; Saito M; Ahmed K; Nishizono A; Handa H; Morishita K
Front Oncol; 2023; 13():1272528. PubMed ID: 38344143
[TBL] [Abstract][Full Text] [Related]
17. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4.
Bjorklund CC; Lu L; Kang J; Hagner PR; Havens CG; Amatangelo M; Wang M; Ren Y; Couto S; Breider M; Ning Y; Gandhi AK; Daniel TO; Chopra R; Klippel A; Thakurta AG
Blood Cancer J; 2015 Oct; 5(10):e354. PubMed ID: 26430725
[TBL] [Abstract][Full Text] [Related]
18. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
[TBL] [Abstract][Full Text] [Related]
19. A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
Liu Y; Huang X; He X; Zhou Y; Jiang X; Chen-Kiang S; Jaffrey SR; Xu G
FASEB J; 2015 Dec; 29(12):4829-39. PubMed ID: 26231201
[TBL] [Abstract][Full Text] [Related]
20. Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100.
Watanabe T; Yamashita S; Ureshino H; Kamachi K; Kurahashi Y; Fukuda-Kurahashi Y; Yoshida N; Hattori N; Nakamura H; Sato A; Kawaguchi A; Sueoka-Aragane N; Kojima K; Okada S; Ushijima T; Kimura S; Sueoka E
Blood; 2020 Aug; 136(7):871-884. PubMed ID: 32391874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]